1. Home
  2. ATOS vs SKYX Comparison

ATOS vs SKYX Comparison

Compare ATOS & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • SKYX
  • Stock Information
  • Founded
  • ATOS 2009
  • SKYX 2004
  • Country
  • ATOS United States
  • SKYX United States
  • Employees
  • ATOS N/A
  • SKYX N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • SKYX Building Products
  • Sector
  • ATOS Health Care
  • SKYX Consumer Discretionary
  • Exchange
  • ATOS Nasdaq
  • SKYX Nasdaq
  • Market Cap
  • ATOS 107.2M
  • SKYX 127.2M
  • IPO Year
  • ATOS 2012
  • SKYX 2022
  • Fundamental
  • Price
  • ATOS $0.78
  • SKYX $1.20
  • Analyst Decision
  • ATOS Strong Buy
  • SKYX Strong Buy
  • Analyst Count
  • ATOS 3
  • SKYX 2
  • Target Price
  • ATOS $6.17
  • SKYX $3.50
  • AVG Volume (30 Days)
  • ATOS 1.3M
  • SKYX 430.3K
  • Earning Date
  • ATOS 08-12-2025
  • SKYX 08-12-2025
  • Dividend Yield
  • ATOS N/A
  • SKYX N/A
  • EPS Growth
  • ATOS N/A
  • SKYX N/A
  • EPS
  • ATOS N/A
  • SKYX N/A
  • Revenue
  • ATOS N/A
  • SKYX $89,028,500.00
  • Revenue This Year
  • ATOS N/A
  • SKYX $18.78
  • Revenue Next Year
  • ATOS N/A
  • SKYX $29.23
  • P/E Ratio
  • ATOS N/A
  • SKYX N/A
  • Revenue Growth
  • ATOS N/A
  • SKYX 5.71
  • 52 Week Low
  • ATOS $0.55
  • SKYX $0.80
  • 52 Week High
  • ATOS $1.66
  • SKYX $2.14
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 45.59
  • SKYX 57.40
  • Support Level
  • ATOS $0.81
  • SKYX $1.10
  • Resistance Level
  • ATOS $0.80
  • SKYX $1.23
  • Average True Range (ATR)
  • ATOS 0.03
  • SKYX 0.09
  • MACD
  • ATOS -0.00
  • SKYX 0.01
  • Stochastic Oscillator
  • ATOS 39.58
  • SKYX 70.37

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About SKYX SKYX Platforms Corp.

SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.

Share on Social Networks: